← Back to Clinical Trials
Recruiting NCT06272552

NCT06272552 Implementing PROMs and PREMs in Routine Clinical Care: Assessment of Requirements and Impact

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06272552
Status Recruiting
Phase
Sponsor Parc de Salut Mar
Condition PROMs
Study Type INTERVENTIONAL
Enrollment 1,440 participants
Start Date 2023-10-25
Primary Completion 2027-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
PROMs and PREMsPREMsControl

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 1,440 participants in total. It began in 2023-10-25 with a primary completion date of 2027-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

There has been increasing interest in the use of patient-reported outcomes and experience measures (PROMs and PREMs) in clinical practice; yet few empirical studies have been conducted to evaluate the usefulness of such implementation. Objective: To evaluate the efficacy of the implementation of PROMs and PREMs in routine clinical care for improving health outcomes and satisfaction with health management. Design: Randomized control trial. Setting: In and outpatient departments of a public hospital in Spain. Participants: 1,440 adult patients managed for breast cancer, prostate cancer, chronic kidney disease, or bariatric surgery. Intervention: Patients will monthly complete, through an App from their smartphones, PROMs and PREMs (arm A, n=480), or only PREMs (arm B, n=480). Responses to PROMs will be transformed into a graphic summary, accessible for physicians and patients at the follow-up visits of the project (9 and 18 months after recruitment). Main outcome measures: Comparison of change among arms on the assessment variables - such as health-related quality of life (EQ-5D-5L), satisfaction with care, or patient-professionals communication. These constructs will be measured at recruitment and at follow up visits for all patients, regardless of their arm allocation (arm C would only be administered these questionnaires, without intervention, n=480). Expected results: Incorporating PROMs and PREMs in routine clinical care may improve patients\' and health professionals\' experiences on health care, as well as improve patients\' health.

Eligibility Criteria

Inclusion Criteria: * Being an active patient of the nephrology service, prostate cancer service, breast cancer service, or bariatric surgery service * In possession of an email account and having basic knowledge of how to manage emails * In possession of a smartphone, computer, or tablet with access to the Internet * Fluent and able to read in Spanish Exclusion Criteria: \- Under 18 years of age

Contact & Investigator

Central Contact

Olatz Garin, PhD

✉ ogarin@researchmar.net

📞 +34 636210255

Principal Investigator

Olatz Garin, PhD

PRINCIPAL INVESTIGATOR

Hospital del Mar Research Institute (IMIM)

Frequently Asked Questions

Who can join the NCT06272552 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying PROMs. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06272552 currently recruiting?

Yes, NCT06272552 is actively recruiting participants. Contact the research team at ogarin@researchmar.net for enrollment information.

Where is the NCT06272552 trial being conducted?

This trial is being conducted at Barcelona, Spain.

Who is sponsoring the NCT06272552 clinical trial?

NCT06272552 is sponsored by Parc de Salut Mar. The principal investigator is Olatz Garin, PhD at Hospital del Mar Research Institute (IMIM). The trial plans to enroll 1,440 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology